Trader Note — 10033 total
Velocity Financial just crossed the finish line. Q1 2026 adjusted EPS came in at $0.68, clearing the $0.64 estimate. Revenue hit $86.9 million against a $53.8 million consensus — a clean beat on both lines. The result…
PHGE enters the week of May 6 carrying one of the most unusual stories in small-cap biotech: a company nominally still in the phage-therapy space is now best known for its Israeli AI defence subsidiary, while its stock…
Revolution Medicines heads into its Q1 2026 earnings release with a rare alignment: a landmark clinical publication, a collapsing short position, and a Wall Street analyst community that has spent two weeks racing to…
Bogota Financial Corp. filed its Q1 2026 earnings on May 6, with the news landing into a week that saw short sellers rapidly exit their positions. The earnings print was modest but positive. Q1 EPS came in at $0.06,…
E-Power Inc. enters the week defined by a single headline: a $252 million microgrid construction deal that would grow the company's power capacity from 3 megawatts to 50 megawatts — yet the stock fell 4.2% on…
The Pennant Group enters the post-earnings session with a clean beat on both the top and bottom line — and a short base that has been quietly shrinking for weeks. Q1 2026 results, released on May 6, showed adjusted EPS…
Datadog prints Q1 results on May 7 with two competing narratives fighting for attention: a stock that has surged 21% in a month and just secured FedRAMP High certification — the passport to U.S. government cloud…
Envista Holdings heads into its May 19 earnings with a genuinely mixed setup: short interest that has climbed sharply over the past month, options traders leaning bullish, and the Street still split between caution and…
SEZL heads into the week after a Q1 earnings release with short sellers rebuilding positions into a rising stock — a setup that puts squeeze dynamics back on the table. The short position is uncomfortably large for…
Castle Biosciences reported Q1 2026 results after the bell on May 6 — a revenue beat against a guidance raise — yet the stock slid 3.6% on May 5 ahead of the print, extending what has been a flat-to-weak few weeks for…
Mirum Pharmaceuticals enters the post-earnings window with a sharply upgraded growth story — Q1 sales of $159.9M beat estimates by 7%, and management lifted full-year guidance to $660M–$680M, well above the consensus…
Fastly gained 31% in a week and 18% in a single session on May 5 — yet short sellers have barely moved, and that tension between a violent price recovery and a stubbornly elevated short base is the defining feature of…
Beyond Meat enters the week of May 6 with a stock that has more than doubled off its lows in a month, a short base that covers nearly a third of the float, and a cost to borrow that just finished unwinding from a…
Palomar Holdings walked into its Q1 2026 earnings report carrying a 12% weekly loss. It walked out with a beat and a $200 million buyback. That combination is the central tension this week: the underlying business…
Western Midstream Partners reports Q1 results on May 7 with short sellers backing away, borrowing costs at a multi-month low, and the Street collectively holding its breath at neutral. Short interest has quietly…
Diversified Energy Company delivered its Q1 2026 results on May 6 alongside a blockbuster acquisition announcement — a combination that puts the stock at a pivotal junction, with two distinct stories competing for the…
Verra Mobility just reported Q1 results. The beat was real. The reaction was not. The company posted Q1 adjusted EPS of $0.25, a cent above the $0.24 consensus estimate. Revenue of $223.6 million came in fractionally…
Green Thumb Industries just handed the cannabis sector a rare piece of good news. Q1 2026 EPS came in at $0.07 against a $0.01 estimate, and revenue of $300.2 million topped the $296.8 million consensus — the clearest…
ECOR enters its Q1 2026 results — scheduled for May 6 — with a stock that has run hard while short sellers look far from alarmed. The week's most interesting tension is the gap between price and positioning. The stock…
Ascendis Pharma enters its Q1 2026 earnings call — scheduled for tomorrow, May 7 — with its ORTEX short score having nearly doubled over the past two weeks, setting up one of the more charged pre-earnings positioning…
